Philip Teresi

Pharmaceutical company Apnimed said its pill, AD109, is a simple-to-use once-daily oral drug that could "expand and reshape the treatment landscape." Armed with findings from critical phase 3 clinical trials, the company said within months, it's set to submit the pill for a New Drug Application with the Food and Drug Administration. Covering hundreds of studies on digital media and health effects over the last 20 years, the review’s findings mark a departure from previous thoughts on screen use.  Please Like, Comment and Follow 'Philip Teresi on KMJ' on all platforms:   ---    Philip Teresi on KMJ is available on the KMJNOW app, Apple Podcasts, Spotify, YouTube or wherever else you listen to podcasts.    --  Philip Teresi on KMJ  Weekdays 2-6 PM Pacific on News/Talk 580 AM & 105.9 FM KMJ    | Website  | Facebook | Instagram | X | Podcast | Amazon |&nb